Bullish option flow detected in Crispr Therapeutics with 9,583 calls trading, 5x expected, and implied vol increasing over 1 point to 63.10%. Feb-24 75 calls and Feb-24 80 calls are the most active options, with total volume in those strikes near 1,700 contracts. The Put/Call Ratio is 0.37. Earnings are expected on February 20th.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $120 from $160 at Truist
- Cathie Wood’s ARK Investment bought 167K shares of Crispr Therapeutics today
- Crispr Therapeutics announces FDA approval for Casgevy
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
- Crispr Therapeutics call volume above normal and directionally bullish